人参皂苷对细胞焦亡的干预作用及在糖尿病肾病中的治疗潜力

韦缘; 周恩超

doi:10.6039/j.issn.1001-0408.2024.24.21

您当前的位置：

首页 >

文章列表页 >

人参皂苷对细胞焦亡的干预作用及在糖尿病肾病中的治疗潜力

综述 | 更新时间：2024-12-26

- 人参皂苷对细胞焦亡的干预作用及在糖尿病肾病中的治疗潜力
- Interventional effects of ginsenoside in pyroptosis and its potential for the treatment of diabetic nephropathy
- 中国药房 2024年35卷第24期页码：3087-3092
- 作者机构：
  
  南京中医药大学附属医院肾内科，南京　210029
- 作者简介：
  
  硕士研究生。研究方向：中医治疗肾病的临床及基础研究。E-mail：13770727468@163.com
  主任中医师，博士生导师，博士。研究方向：中医治疗肾病的临床及基础研究。E-mail：zhouenchao@njucm.edu.cn
- 基金信息：
  
  江苏省科技计划专项资金（重点研发计划社会发展）项目(BE2023791)
- DOI：10.6039/j.issn.1001-0408.2024.24.21
  中图分类号： R285
- 纸质出版日期：2024-12-30，
  
  收稿日期：2024-07-10，
  
  修回日期：2024-12-07，
- 稿件说明：
移动端阅览
韦缘,周恩超.人参皂苷对细胞焦亡的干预作用及在糖尿病肾病中的治疗潜力[J].中国药房,2024,35(24):3087-3092.

WEI Yuan,ZHOU Enchao.Interventional effects of ginsenoside in pyroptosis and its potential for the treatment of diabetic nephropathy[J].ZHONGGUO YAOFANG,2024,35(24):3087-3092.
韦缘,周恩超.人参皂苷对细胞焦亡的干预作用及在糖尿病肾病中的治疗潜力[J].中国药房,2024,35(24):3087-3092. DOI： 10.6039/j.issn.1001-0408.2024.24.21.

WEI Yuan,ZHOU Enchao.Interventional effects of ginsenoside in pyroptosis and its potential for the treatment of diabetic nephropathy[J].ZHONGGUO YAOFANG,2024,35(24):3087-3092. DOI： 10.6039/j.issn.1001-0408.2024.24.21.

摘要

糖尿病肾病（DN）是糖尿病患者常见的并发症之一，是导致终末期肾病的主要原因。细胞焦亡是一种程序性细胞死亡方式，在DN的发生发展中起着重要作用。足细胞、肾小球内皮细胞和肾小管上皮细胞的焦亡会导致肾损伤和功能障碍，从而加速DN的进展。研究表明，多种人参皂苷在抑制细胞焦亡相关通路方面具有潜力，从而为DN治疗提供了新的思路。其中，人参皂苷化合物K、Rg5、Rg1、Rh2和Rb1等可通过调节核苷酸结合结构域富含亮氨酸重复序列和含热蛋白结构域受体3炎症小体通路中的关键蛋白（如胱天蛋白酶1、核因子κB、焦孔素D蛋白氮端片段、白细胞介素1β和白细胞介素18等），抑制炎症反应和细胞焦亡，从而发挥对DN的干预作用。然而，目前大部分研究集中于动物模型，尚需进一步的临床试验来验证人参皂苷在人体中的疗效和安全性；同时，还需深入探索不同个体对人参皂苷的反应差异，以及人参皂苷针对细胞焦亡途径的精细调节机制，以优化治疗效果并减少潜在的副作用。

Abstract

Diabetic nephropathy （DN） is a common complication of diabetes and the leading cause of end-stage renal disease. Pyroptosis is a mode of programmed cell death that plays an important role in the development of DN. Pyroptosis of podocytes， glomerular endothelial cells and tubular epithelial cells leads to renal injury and dysfunction， accelerating the progression of DN. In recent years， studies have shown that a variety of ginsenosides have the potential to inhibit pyroptosis-related pathways， providing new ideas for DN treatment. Among them， ginsenoside compound K， ginsenoside Rg5， ginsenoside Rg1， ginsenoside Rh2 and ginsenoside Rb1 exert a protective effect against DN by regulating nucleotide-binding domain-rich repeat and pyrin domain-containing protein 3 inflammatory vesicle pathway， such as caspase-1， nuclear factor-κB， gasdermin D-N， interleukin-1β （IL-1β） and IL-18， thereby inhibiting inflammation and cellular pyroptosis. However， most current studies have focused on animal models， and further clinical trials are needed to verify the efficacy and safety of ginsenosides in humans. In addition， future studies need to explore the differences in response to ginsenosides in different individuals and the fine-tuning mechanism of ginsenosides against the cellular pyroptosis pathway to optimize therapeutic efficacy and reduce potential side effects.

关键词

人参皂苷糖尿病肾病细胞焦亡作用机制炎症反应

Keywords

ginsenosidesdiabetic nephropathypyroptosismechanism of actioninflammation

references

北京大学医学系糖尿病肾脏病专家共识协作组. 糖尿病肾脏病诊治专家共识[J]. 中华医学杂志，2020，100（4）：247-260.

Diabetes Kidney Expert Consensus Cooperation Group of Peking University Medical Department.Expert consensus on diagnosis and treatment of diabetic nephropathy[J]. Natl Med J China，2020，100（4）：247-260.

CHENG H T，XU X Q，LIM P S，et al. Worldwide epidemiology of diabetes-related end-stage renal disease，2000-2015[J]. Diabetes Care，2021，44（1）：89-97.

曹东维，朱大龙. 我国糖尿病患者合并肾病的现状[J]. 中国科学：生命科学，2018，48（8）：866-871.

CAO D W，ZHU D L. Kidney disease incidence in patients with diabetes mellitus in China[J]. Sci Sin Vitae，2018，48（8）：866-871.

CUEVAS S，PELEGRÍN P. Pyroptosis and redox balance in kidney diseases[J]. Antioxid Redox Signal，2021，35（1）：40-60.

ZHUANG Y B，DING G X，ZHAO M，et al. NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function[J]. J Biol Chem，2014，289（36）：25101-25111.

杨玉，陈春林. 人参皂苷Rg3的药理作用研究现状[J]. 中国临床药理学杂志，2019，35（5）：497-500.

YANG Y，CHEN C L. Current situation of ginsenoside Rg3 on the pharmacological effects[J]. Chin J Clin Pharmacol，2019，35（5）：497-500.

刘文华，望永鼎，翟一飞，等. 人参皂苷Rg1介导PI3K/AKT/FOXO3通路缓解高糖诱导的肾小球系膜细胞氧化应激反应[J]. 免疫学杂志，2020，36（4）：285-291.

LIU W H，WANG Y D，ZHAI Y F，et al. Ginsenoside Rg1 alleviates the oxidative stress in mesangial cells induced by high glucose through PI3K/AKT/FOXO3 pathway[J]. Immunol J，2020，36（4）：285-291.

沈炳香，王法财，周艺，等. 人参皂苷Rh2调控盘状结构域受体1对糖尿病大鼠肾纤维化和细胞凋亡的影响[J]. 南方医科大学学报，2021，41（7）：1107-1113.

SHEN B X，WANG F C，ZHOU Y，et al. Ginsenoside Rh2 inhibits renal fibrosis and renal cell apoptosis in rats with diabetic nephropathy by downregulating discoid domain receptor 1[J]. J South Med Univ，2021，41（7）：1107-1113.

赵为陈，何春远，王法财. 以caspase-1介导细胞焦亡筛选治疗糖尿病肾病潜在的中药及单体成分[J]. 南方医科大学学报，2020，40（9）：1280-1287.

ZHAO W C，HE C Y，WANG F C. Screening potential Chinese materia medica and their monomers for treatment of diabetic nephropathy based on caspase-1-mediated pyroptosis[J]. J South Med Univ，2020，40（9）：1280-1287.

SONG W，WEI L，DU Y W，et al. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/strepto-zotocin-induced diabetic mice[J]. Int Immunopharmacol，2018，63：227-238.

BAI L T，GAO J L，WEI F，et al. Therapeutic potential of ginsenosides as an adjuvant treatment for diabetes[J]. Front Pharmacol，2018，9：423.

TAWAB M A，BAHR U，KARAS M，et al. Degradation of ginsenosides in humans after oral administration[J]. Drug Metab Dispos，2003，31（8）：1065-1071.

KIM H K. Pharmacokinetics of ginsenoside Rb1 and its metabolite compound K after oral administration of Korean Red Ginseng extract[J]. J Ginseng Res，2013，37（4）：451-456.

CHOI M K，JIN S，JEON J H，et al. Tolerability and pharmacokinetics of ginsenosides Rb1，Rb2，Rc，Rd，and compound K after single or multiple administration of red ginseng extract in human beings[J]. J Ginseng Res，2020，44（2）：229-237.

KIM H J，OH T K，KIM Y H，et al. Pharmacokinetics of ginsenoside Rb1，Rg3，Rk1，Rg5，F2，and compound K from Red Ginseng extract in healthy Korean volunteers[J]. Evid Based Complement Alternat Med，2022，2022：8427519.

SHI J J，GAO W Q，SHAO F. Pyroptosis：gasdermin-mediated programmed necrotic cell death[J]. Trends Biochem Sci，2017，42（4）：245-254.

WANG Y P，GAO W Q，SHI X Y，et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature，2017，547（7661）：99-103.

ZHOU Z W，HE H B，WANG K，et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyropto-sis in target cells[J]. Science，2020，368（6494）：eaaz7548.

ZHANG Z B，ZHANG Y，XIA S Y，et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J]. Nature，2020，579（7799）：415-420.

DENG W Y，BAI Y，DENG F，et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis[J]. Nature，2022，602（7897）：496-502.

CHENG Q，PAN J，ZHOU Z L，et al. Caspase-11/4 and gasdermin D-mediated pyroptosis contribute to podocyte injury in mouse diabetic nephropathy[J]. Acta Pharmacol Sin，2021，42（6）：954-963.

ZUO Y，CHEN L，HE X Y，et al. Atorvastatin regulates MALAT1/miR-200c/NRF2 activity to protect against podocyte pyroptosis induced by high glucose[J]. Diabetes Metab Syndr Obes，2021，14：1631-1645.

ZHU W，LI Y Y，ZENG H X，et al. Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosis[J]. Int Immunopharmacol，2021，101（Pt. B）：108236.

LI F T，CHEN Y，LI Y J，et al. Geniposide alleviates diabetic nephropathy of mice through AMPK/SIRT1/NF-κB pathway[J]. Eur J Pharmacol，2020，886：173449.

CHEN S J，LV L L，LIU B C，et al. Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease[J]. Cell Prolif，2020，53（3）：e12763.

温洁，高颖颖. 银杏素调节NF-κB/NLRP3/Caspase-1信号通路对高糖诱导肾小球内皮细胞焦亡的影响[J]. 河北医药，2023，45（15）：2251-2255，2260.

WEN J，GAO Y Y. Ginkgo biloba extract regulates high-glucose-induced pyroptosis in glomerular endothelial cells by mediating the NF-κB/NLRP3/Caspase-1 signaling pathway[J]. Hebei Med J，2023，45（15）：2251-2255，2260.

SHEN Y L，CHEN W，LIN K H，et al. Notoginsenoside Fc，a novel renoprotective agent，ameliorates glomerular endothelial cells pyroptosis and mitochondrial dysfunction in diabetic nephropathy through regulating HMGCS2 pathway[J]. Phytomedicine，2024，126：155445.

吕佳，郝亚宁，王晓培，等. 骨髓间充质干细胞来源外泌体miR-30e-5p改善高血糖诱发的肾小管上皮细胞的焦亡[J]. 西安交通大学学报（医学版），2023，44（6）：859-865.

LYU J，HAO Y N，WANG X P，et al. Bone marrow me-senchymal stem cell-derived exosomal miR-30e-5p amelio-rates high-glucose induced renal proximal tubular cell pyroptosis[J]. J Xi’an Jiaotong Univ Med Sci，2023，44（6）：859-865.

KE R Q，WANG Y，HONG S H，et al. Endoplasmic reticulum stress related factor IRE1α regulates TXNIP/NLRP3-mediated pyroptosis in diabetic nephropathy[J]. Exp Cell Res，2020，396（2）：112293.

WEN S，DENG F，LI L L，et al. VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis and inflammation[J]. J Diabetes Investig，2022，13（1）：22-33.

JIA Y，XU H，YU Q，et al. Identification and verification of vascular cell adhesion protein 1 as an immune-related Hub gene associated with the tubulointerstitial injury in diabetic kidney disease[J]. Bioengineered，2021，12（1）：6655-6673.

CHEN W J，WANG J L，LUO Y，et al. Ginsenoside Rb1 and compound K improve insulin signaling and inhibit ER stress-associated NLRP3 inflammasome activation in adipose tissue[J]. J Ginseng Res，2016，40（4）：351-358.

TIAN Y C，FENG X Y，ZHOU Z M，et al. Ginsenoside compound K ameliorates osteoarthritis by inhibiting the chondrocyte endoplasmic reticulum stress-mediated IRE1α-TXNIP-NLRP3 axis and pyroptosis[J]. J Agric Food Chem，2023，71（3）：1499-1509.

WEI Y G，YANG H X，ZHU C H，et al. Ginsenoside Rg5 relieves type 2 diabetes by improving hepatic insulin resistance in db/db mice[J]. J Funct Foods，2020，71：104014.

ZHU Y Y，ZHU C H，YANG H X，et al. Protective effect of ginsenoside Rg5 against kidney injury via inhibition of NLRP3 inflammasome activation and the MAPK signa-ling pathway in high-fat diet/streptozotocin-induced diabetic mice[J]. Pharmacol Res，2020，155：104746.

HAN Y L，SU Y，HAN M，et al. Ginsenoside Rg1 attenua-tes glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice[J]. J Ethnopharmacol，2023，302（Pt. A）：115923.

WANG T，GAO Y B，YUE R C，et al. Ginsenoside Rg1 alleviates podocyte injury induced by hyperlipidemia via targeting the mTOR/NF-κB/NLRP3 axis[J]. Evid Based Complement Alternat Med，2020，2020：2735714.

滕杰，陈业刚. 人参皂苷Rg1抑制NLRP3/Caspase-1通路抵抗肾纤维化的作用研究[J]. 天津医科大学学报，2023，29（4）：398-405.

TENG J，CHEN Y G. Effect of ginsenoside Rg1 on inhibition of NLRP3/Caspase-1 pathway against renal fibrosis[J]. J Tianjin Med Univ，2023，29（4）：398-405.

ZHANG R R，GUAN S，MENG Z Q，et al. Ginsenoside Rb1 alleviates 3-MCPD-induced renal cell pyroptosis by activating mitophagy[J]. Food Chem Toxicol，2024，186：114522.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

甘地胶囊辅助治疗糖尿病肾病的疗效观察

骨化三醇联合盐酸吡格列酮对早期糖尿病肾病患者相关指标的影响

二甲双胍联合骨化三醇对2型糖尿病患者肾功能及视网膜的保护作用

琥珀酸亚铁对比生血宁辅助治疗糖尿病肾病腹膜透析患者肾性贫血的临床观察

阿魏酸哌嗪联合谷胱甘肽治疗糖尿病肾病的临床观察